Ethical considerations in psychopharmacological research involving decisionally impaired subjects
- 28 May 2003
- journal article
- review article
- Published by Springer Nature in Psychopharmacology
- Vol. 171 (1) , 92-97
- https://doi.org/10.1007/s00213-003-1503-1
Abstract
Rationale Research subjects who are unable to provide informed consent must be protected from exploitation. The federal regulations governing human subjects research mandate additional protections for "mentally disabled" subjects but include neither a definition of this "vulnerable" population nor any guidance on what safeguards should be employed or how they should be implemented. Objectives This article begins with a definition of vulnerability due to a mental disorder in the context of the clinical research setting. It is organized along the following sequential phases of psychopharmacological research: study design and methodology; protocol review; subject recruitment and enrollment; conduct and monitoring of the study; and manuscript preparation and publication. Practical recommendations are then offered to clinical researchers and Institutional Review Boards (IRBs) for implementing additional protections for decisionally impaired subjects at each phase of the psychopharmacological research process. Methods A computer-assisted literature review was performed to identify descriptions of safeguards for decisionally impaired subjects. Recommendations for additional protections were also drawn from the authors' experiences with the IRB review process and the conduct and monitoring of clinical research with decisionally impaired subjects. Results The use of informed consent monitoring and the independent assessment of decision-making capacity are two feasible safeguards that IRBs can mandate for research with decisionally impaired subjects. There has been little systematic implementation of other safeguards such as research advance directives or prospective authorization for research participation. Conclusions Clinical investigators and IRBs are under considerable scrutiny with respect to the protection of decisionally impaired research subjects. There is a pressing need for data-driven strategies for the optimal protection of decisionally impaired research subjects.Keywords
This publication has 28 references indexed in Scilit:
- Impaired Decision-Making Ability in Subjects With Alzheimer’s Disease and Willingness to Participate in ResearchAmerican Journal of Psychiatry, 2002
- Informed Consent for Medical Research by the ElderlyExperimental Aging Research, 2002
- The Ethics of Placebo-Controlled Trials — A Middle GroundNew England Journal of Medicine, 2001
- Assessing the Competence of Persons With Alzheimer’s Disease in Providing Informed Consent for Participation in ResearchAmerican Journal of Psychiatry, 2001
- What Makes Clinical Research Ethical?JAMA, 2000
- Uneasy Alliance — Clinical Investigators and the Pharmaceutical IndustryNew England Journal of Medicine, 2000
- Review Article Imiquimod applied topically: a novel immune response modifier and new class of drugInternational Journal of Immunopharmacology, 1999
- Professional Integrity in Clinical ResearchPublished by American Medical Association (AMA) ,1998
- Understanding Financial Conflicts of InterestNew England Journal of Medicine, 1993
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960